Nature Publishing Group, publisher of Nature, and other science journals and reference works NATURE.COM NATURE NEWS NATUREJOBS NATUREEVENTS ABOUT NPG
Help Nature.com site index  
Leukemia
SEARCH     advanced search my account e-alerts subscribe register
Journal home
Advance online publication
Current issue
Archive
Press releases
For authors
For referees
Contact editorial office
About the journal
For librarians
Subscribe
Advertising
naturereprints
Contact NPG
Customer services
Site features
NPG Subject areas
Access material from all our publications in your subject area:
Biotechnology Biotechnology
Cancer Cancer
Chemistry Chemistry
Dentistry Dentistry
Development Development
Drug Discovery Drug Discovery
Earth Sciences Earth Sciences
Evolution & Ecology Evolution & Ecology
Genetics Genetics
Immunology Immunology
Materials Materials Science
Medical Research Medical Research
Microbiology Microbiology
Molecular Cell Biology Molecular Cell Biology
Neuroscience Neuroscience
Pharmacology Pharmacology
Physics Physics
Browse all publications
 
May 1999, Volume 13, Number 5, Pages 719-728
Table of contents    Previous  Abstract  Next   Article  PDF
Original manuscript: apoptosis
Cleavage of Bcl-2 is an early event in chemotherapy-induced apoptosis of human myeloid leukemia cells
B Fadeel1,2, Z Hassan3,4, E Hellström-Lindberg3,4, J-I Henter2, S Orrenius1 and B Zhivotovsky1,a

1Institute of Environmental Medicine, Division of Toxicology, Karolinska Institutet, Stockholm, Sweden

2Childhood Cancer Research Unit, Karolinska Hospital, Stockholm, Sweden

3Department of Hematology, Huddinge University Hospital, Huddinge, Sweden

4Department of Medicine, Karolinska Institutet, Stockholm, Sweden

aCorrespondence: B Zhivotovsky, Institute of Environmental Medicine, Division of Toxicology, Karolinska Institutet, 171 77 Stockholm, Sweden; Fax: + 46 8 32 90 41

Abstract

The proto-oncogene product Bcl-2 protects a wide variety of cell types from apoptosis via a hitherto unknown mechanism. Bcl-2 has been shown to function upstream of the death proteases (caspases) in some, but not all, occurrences of apoptotic cell death. Using the myeloid leukemic cell line P39 we report the chemotherapy-induced caspase-dependent cleavage of endogenous Bcl-2. Etoposide treatment of these cells triggered a time-dependent activation of type II and type III caspases and cleavage of Bcl-2 yielding a 23 kDa cleavage fragment. The emergence of this cleavage product was blocked by the general caspase inhibitor zVAD-fmk, as well as the type III caspase inhibitor IETD-fmk and the caspase-9-selective inhibitor LEHD-fmk, while the type II caspase inhibitor DEVD-fmk proved considerably less efficient. Bcl-2 cleavage preceded cleavage of the known caspase-3 substrate, poly(ADP-ribose) polymerase (PARP), as well as that of the caspase-6 substrate, lamin B, indicating that Bcl-2 cleavage is a relatively early event in the apoptosis cascade in this experimental model. While evidence for cleavage of Bcl-2 in several subcellular compartments of etoposide-treated cells was obtained, this cleavage was detected predominantly in the mitochondrial fraction, thus providing further support for the central role of mitochondria in apoptosis. Caspase-mediated cleavage following etoposide treatment of these myeloid leukemic cells may represent a means for the attenuation of Bcl-2 function upon apoptosis induction.

Keywords

apoptosis; Bcl-2; caspases; chemotherapy; cleavage

Received 22 October 1998; accepted 2 February 1999
May 1999, Volume 13, Number 5, Pages 719-728
Table of contents    Previous  Abstract  Next   Article  PDF
Privacy Policy © 1999 Nature Publishing Group